Bright Minds Biosciences (NasdaqCM:DRUG) Update / Briefing Transcript

Bright Minds Biosciences (NasdaqCM:DRUG) Update / Briefing January 06, 2026 08:00 AM ET Company ParticipantsJan Torleif Pedersen - Chief Scientific OfficerIan McDonald - CEOStephen Collins - Chief Medical OfficerIan McDonaldGood morning, and thank you for joining us. This is Ian McDonald, Chief Executive Officer of Bright Minds Biosciences. Today we're reporting the top-line data from the phase II breakthrough study of BMB-101 in adults with drug-resistant absence seizures, as well as developmental and epil ...